Biotech Values

[biomaven0]

Tofacitinib hits JAK3, it works out fine.

Doesn't imply that if JAK3 is all you hit (as VRTX does) that you will be OK. It might turn out to be a dosage issue - you can partially inhibit JAK1 and JAK3 say, or you can more fully inhibit JAK3 by itself to get the same efficacy, but maybe with more problems with infections.

When I was talking about the INCY compound I did not mean their myelofibrosis compound - I meant their RA version:

http://investor.incyte.com/phoenix.zhtml?c=69764&p=irol-newsArticle&ID=1494997&highlight=

Peter